{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.3","upperLimit":"51.8","value":"18.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"}],"units":"Participants"}],"description":"Percent of patients and the 95% Binomial Confidence interval who were alive and free of progression at 12 months following transplant for the patients in Phase II. Progression will be based on International Myeloma Working Group criteria where patients may meet any one of the following criteria - increase of 25% or more in serum or urine M-protein from baseline, Serum M-protein and/or the absolute increase must be \\>=0.5 g/dl, Urine M-protein and/or absolute increase must be \\>=200 mg/24 hours, development of new bone lesions or soft tissue plasmacyomas or definite increase in the size of existing bone lesions or soft tissue plasmacyomas, or development of hypercalcemia (corrected serum Ca++\\>11.5 mg/dl) that can be attributed solely to plasma cell proliferative disease.","dispersionType":"95% Confidence Interval","groups":[{"description":"Standard treatment of sirolimus and tacrolimus as GvHD prophylaxis with sirolimus (target plasma drug level of 5-10 ng/ml) and lenalidomide (15 mg daily) as post-transplant maintenance","id":"OG000","title":"Phase II"}],"paramType":"NUMBER","populationDescription":"All patients who received treatment and were followed after transplant.","reportingStatus":"POSTED","timeFrame":"Transplant (Day 0) through 1 year post-transplant","title":"Phase II: Percent of Patients Alive and Free of Progression at 12 Months Following Transplant","type":"PRIMARY","unitOfMeasure":"percentage of participants"}